Short Interest in Agenus Inc. (NASDAQ:AGEN) Drops By 10.5%

Agenus Inc. (NASDAQ:AGEN) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 2,800,000 shares, a decrease of 10.5% from the October 15th total of 3,130,000 shares. Based on an average daily volume of 393,300 shares, the days-to-cover ratio is presently 7.1 days. Currently, 13.2% of the company’s shares are sold short.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Agenus by 13.7% in the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after acquiring an additional 4,134,232 shares during the period. Acadian Asset Management LLC increased its stake in Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares in the last quarter. Geode Capital Management LLC raised its position in Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares during the last quarter. State Street Corp raised its holdings in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after acquiring an additional 9,731 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Stock Down 1.8 %

Shares of Agenus stock opened at $2.72 on Monday. Agenus has a 52-week low of $2.58 and a 52-week high of $19.69. The company has a market capitalization of $63.81 million, a P/E ratio of -0.24 and a beta of 1.39. The company has a 50 day moving average of $4.70 and a 200 day moving average of $8.64.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. HC Wainwright reduced their price objective on shares of Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, November 12th. B. Riley decreased their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Agenus currently has an average rating of “Hold” and a consensus price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.